<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904134</url>
  </required_header>
  <id_info>
    <org_study_id>BMT CTN 1702</org_study_id>
    <secondary_id>5U24HL138660-02</secondary_id>
    <secondary_id>N00014-18-1-2888</secondary_id>
    <nct_id>NCT03904134</nct_id>
  </id_info>
  <brief_title>Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation</brief_title>
  <acronym>BMT CTN 1702</acronym>
  <official_title>Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for International Blood and Marrow Transplant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for International Blood and Marrow Transplant Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a search strategy of searching for an
      HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative
      donor if an HLA-matched unrelated donor is not available versus proceeding directly to an
      alternative donor transplant will result in better survival for allogeneic transplant
      recipients within 2 years after study enrollment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, interventional and observational study to understand factors affecting
      the likelihood of transplantation in patients without a human leukocyte antigen (HLA) matched
      family donor and to compare outcomes associated with pursuing an HLA-identical unrelated
      versus other alternative donor graft sources. Alternative donors are defined as any donor
      other than an HLA-matched or 1 antigen-mismatched related donor. Patients with acute myeloid
      leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS),
      Non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), acquired aplastic anemia (AA) or sickle
      cell disease (SCD) are eligible. The primary comparison for the interventional study will be
      between two arms based on biologic assignment, analyzed on an intention-to-treat basis: Arm
      1: Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a
      &gt;90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated
      donor will be pursued; and Arm 2: Patients who are Very Unlikely to find a MUD, defined as
      having a &lt;10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a
      haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
      Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other
      two groups (a 26% chance), will be enrolled onto the observational component of the study and
      analyzed for all relevant endpoints but will not be included in the primary comparison.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The primary comparison for the interventional study will be between two arms based on biologic assignment, analyzed on an intention-to-treat basis: Arm 1: Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a &gt;90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued; and Arm 2: Patients who are Very Unlikely to find a MUD, defined as having a &lt;10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued. Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival for MUD Very Likely and MUD Very Unlikely Arms</measure>
    <time_frame>2 years</time_frame>
    <description>Compare overall survival between Very Likely to find a matched unrelated donor search prognosis patients and Very Unlikely to find a matched unrelated donor search prognosis patients who are evaluable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Transplant by Donor Search Prognosis Score</measure>
    <time_frame>2 years</time_frame>
    <description>To estimate and compare the cumulative incidence of receiving a transplant according to donor search prognosis, regardless of donor search prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barriers to Transplant</measure>
    <time_frame>2 years</time_frame>
    <description>To describe barriers to achieving transplantation with different donor search strategies, regardless of donor search prognosis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival in patients transplanted for malignant diseases</measure>
    <time_frame>2 years</time_frame>
    <description>To compare overall survival in patients transplanted for malignant diseases, according to the donor search prognosis and the alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Relapse in patients transplanted for malignant diseases</measure>
    <time_frame>2 years</time_frame>
    <description>To compare relapse in patients transplanted for malignant diseases, according to the donor search prognosis and the alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease-free survival in patients transplanted for malignant diseases</measure>
    <time_frame>2 years</time_frame>
    <description>To compare disease-free survival, treatment-related mortality, and acute and chronic GVHD in patients transplanted for malignant diseases, according to the donor search prognosis and the alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-related mortality in patients transplanted for malignant diseases</measure>
    <time_frame>2 years</time_frame>
    <description>To compare treatment-related mortality in patients transplanted for malignant diseases, according to the donor search prognosis and the alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute and chronic GVHD in patients transplanted for malignant diseases</measure>
    <time_frame>2 years</time_frame>
    <description>To compare acute and chronic GVHD in patients transplanted for malignant diseases, according to the donor search prognosis and the alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Survival in patients with acquired aplastic anemia and sickle cell disease after transplantation</measure>
    <time_frame>2 years</time_frame>
    <description>To describe survival in patients with acquired aplastic anemia and sickle cell disease after transplantation, according to the donor search prognosis and the alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute and chronic GVHD in patients with acquired aplastic anemia and sickle cell disease after transplantation</measure>
    <time_frame>2 years</time_frame>
    <description>To describe acute and chronic GVHD in patients with acquired aplastic anemia and sickle cell disease after transplantation, according to the donor search prognosis and the alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>AML or ALL in first complete remission or early stage MDS Substudy - QoL</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to compare QOL, according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>AML or ALL in first complete remission or early stage MDS Substudy - primary graft failure</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the incidence of primary graft failure, according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>AML or ALL in first complete remission or early stage MDS Substudy - chronic GVHD</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the incidence of chronic GVHD, according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>AML or ALL in first complete remission or early stage MDS Substudy - time until off systemic immunosuppression</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe time until off systemic immunosuppression, according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>AML or ALL in first complete remission or early stage MDS Substudy - GRFS</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the incidence of acute grade III-IV and chronic GVHD requiring immunosuppression-free, relapse-free survival (GRFS), according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>AML or ALL in first complete remission or early stage MDS Substudy - CRFS</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the incidence of moderate-severe chronic GVHD relapse-free survival (CRFS), according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>AML or ALL in first complete remission or early stage MDS Substudy - current CRFS</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the incidence of current CRFS (still on systemic treatment for cGVHD), according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>QOL Substudy - number of hospital days</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the number of hospital days in the first 100 post-transplant days, according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>QOL Substudy - infections</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the incidence of infections, according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>QOL Substudy - immune reconstitution</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the incidence of immune reconstitution, according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <other_outcome>
    <measure>QOL Substudy - late effects after transplantation</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with AML or ALL in first complete remission or early stage MDS treated with a limited subset of conditioning and GVHD prophylaxis regimens and transplanted with either matched unrelated donors or haploidentical related donors (QOL Substudy), to describe the late effects after transplantation, according to the donor search prognosis and alternative donor used.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1732</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Acquired Aplastic Anemia</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Donor Search Prognosis: MUD Very Likely</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a &gt;90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donor Search Prognosis: MUD Very Unlikely</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who are Very Unlikely to find a MUD, defined as having a &lt;10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donor Search Prognosis: MUD Less Likely</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Donor Search Prognosis Score</intervention_name>
    <description>Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.</description>
    <arm_group_label>Donor Search Prognosis: MUD Less Likely</arm_group_label>
    <arm_group_label>Donor Search Prognosis: MUD Very Likely</arm_group_label>
    <arm_group_label>Donor Search Prognosis: MUD Very Unlikely</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients fulfilling the inclusion criteria will be eligible for enrollment in this study.
        Of those who consent, only patients who lack a suitable HLA-identical or 1 allele or
        antigen mismatched related donors are evaluable. Patients with an HLA-identical sibling or
        1 allele or antigen mismatched family member donor are evaluable as long as the center
        deems the family member donor as unsuitable for other reasons. Patients may co-enroll with
        other interventional or observational studies.

          1. Patients of all ages with AML, ALL, MDS, NHL, HL, AA, or SCD are eligible.

          2. Any planned conditioning regimen and GVHD prophylaxis approach is eligible.

          3. Patients must be considered suitable allogeneic transplant candidates at the time of
             enrollment based on medical history, physical examination, and available laboratory
             tests. Specific testing for organ function is not required for eligibility but, if
             available, these tests should be used by the treating physician to judge transplant
             suitability.

          4. Patient and physician must intend to proceed with allogeneic HCT within the next 6
             months if a suitable donor is identified.

          5. Center plans to follow the algorithm for alternative donor identification: (a) for
             subjects who are Very Likely to find a MUD, attempt to identify a matched unrelated
             donor; (b) for a subjects who are Very Unlikely to find a MUD, proceed expeditiously
             to a haploidentical, cord blood or mismatched unrelated donor.

          6. Signed informed consent, and assent if applicable. Consent may be signed prior to
             completion of family typing but patients will only be considered evaluable upon
             confirmation that there is no suitable HLA-identical or 1 allele or antigen mismatched
             related donor available.

        Exclusion Criteria:

          1. Prior allogeneic HCT (prior autologous transplant is allowed)

          2. Previous formal unrelated donor search
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie J Lee, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Ciurea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Vogel</last_name>
    <phone>763-406-8691</phone>
    <email>jvogel@nmdp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Leckrone</last_name>
    <email>eleckron@nmdp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monzr Al Malki, MD</last_name>
      <phone>401-456-5790</phone>
      <email>malmalki@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Sandy Tran</last_name>
      <phone>626-218-7726</phone>
      <email>santran@coh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Monzr Al Malki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divya Koura, MD</last_name>
      <phone>858-822-6600</phone>
      <email>dkoura@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Padilla</last_name>
      <email>mlp002@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Divya Koura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pulsipher, MD</last_name>
      <phone>323-361-8840</phone>
      <email>mpulsipher@chla.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Arieli</last_name>
      <email>karieli@chla.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Pulsipher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Arai, MD</last_name>
      <phone>650-723-0822</phone>
      <email>sarai1@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle Nguyen</last_name>
      <phone>650-723-4358</phone>
      <email>itnguyen@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sally Arai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Wingard, MD</last_name>
      <phone>352-273-8010</phone>
      <email>wingajr@medicine.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Rosenau</last_name>
      <phone>352-294-8938</phone>
      <email>roseeg@ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Wingard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Pidala, MD, PhD</last_name>
      <phone>813-745-7202</phone>
      <email>joseph.pidala@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Karlie Balke</last_name>
      <phone>813-745-5919</phone>
      <email>karlie.balke@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Pidala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Langston, MD</last_name>
      <email>alangst@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Loizos Nikolaou</last_name>
      <phone>404-778-8658</phone>
      <email>loizos.nikolaou@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amelia Langston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asad Bashey, MD, PhD</last_name>
      <phone>404-255-1930</phone>
      <email>abashey@bmtga.com</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Guzowski</last_name>
      <phone>404-851-8523</phone>
      <email>caitlin.curran@Northside.com</email>
    </contact_backup>
    <investigator>
      <last_name>Asad Bashey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Stiff, MD</last_name>
      <phone>708-327-3148</phone>
      <email>pstiff@lumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Lee</last_name>
      <phone>708-327-2241</phone>
      <email>mlee@luc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Stiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherif Farag, MD, PhD</last_name>
      <phone>317-274-0460</phone>
      <email>ssfarag@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jack Wilson II</last_name>
      <phone>317-278-7866</phone>
      <email>jaerwils@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sherif Farag, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Yared, MD</last_name>
      <phone>410-328-1230</phone>
      <email>jyared@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sherri Bauman</last_name>
      <phone>410-328-1230</phone>
      <email>sbauman@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jean Yared, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rizwan Romee, MD</last_name>
      <phone>617-632-3470</phone>
      <email>Rizwan_Romee@dfci.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Peter Stowe</last_name>
      <phone>617-632-5502</phone>
      <email>Peter_Stowe@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rizwan Romee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Maciejewski, MD, PhD</last_name>
      <phone>734-936-8785</phone>
      <email>maciejew@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Connie Varner</last_name>
      <phone>734-615-2742</phone>
      <email>convarne@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Maciejewski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Uberti, MD, PhD</last_name>
      <phone>313-576-8754</phone>
      <email>ubertij@karmanos.org</email>
    </contact>
    <contact_backup>
      <last_name>Marie Ventimiglia</last_name>
      <phone>313-576-9271</phone>
      <email>ventimim@karmanos.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Uberti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Brunstein, MD, PhD</last_name>
      <phone>612-625-8942</phone>
      <email>bruns072@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenna Johnson</last_name>
      <phone>612-624-9712</phone>
      <email>joh03025@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Claudio Brunstein, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Hogan, MB, BCh</last_name>
      <phone>507-266-4917</phone>
      <email>hogan.william@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Hull</last_name>
      <phone>507-422-4820</phone>
      <email>Hull.Jennifer2@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Hogan, MB, BCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Westervelt, MD, PhD</last_name>
      <phone>314-454-8365</phone>
      <email>pwestervelt@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adebayo (Bayo) Adekunle</last_name>
      <phone>314-362-2582</phone>
      <email>aadekunle@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Westervelt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rosewell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip McCarthy, MD</last_name>
      <phone>716-845-8564</phone>
      <phone_ext>1444</phone_ext>
      <email>philip.mccarthy@roswellpark.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Dubel</last_name>
      <email>Karen.dubel@roswellpark.org</email>
    </contact_backup>
    <investigator>
      <last_name>Philip McCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Perales, MD</last_name>
      <phone>212-639-8682</phone>
      <email>peralesm@MSKCC.ORG</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Hoover</last_name>
      <phone>646-888-8570</phone>
      <email>hoovere@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Miguel Perales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcie Riches, MD, MS</last_name>
      <phone>919-966-4431</phone>
      <email>Marcie_riches@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janell Markey</last_name>
      <phone>919-983-0931</phone>
      <email>janell_markey@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marcie Riches, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Grunwald, MD</last_name>
      <phone>980-442-2000</phone>
      <email>Michael.Grunwald@atriumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra White</last_name>
      <phone>980-442-2344</phone>
      <email>Alexandra.M.White@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Grunwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Kurtzberg, MD</last_name>
      <phone>919-668-1100</phone>
      <email>Kurtz001@mc.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Baker</last_name>
      <phone>919-668-6536</phone>
      <email>jennifer.hungate@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joanne Kurtzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitchell Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Howard, MD</last_name>
      <phone>336-716-7972</phone>
      <email>dhoward@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brittany Choi, RN</last_name>
      <phone>336-713-6928</phone>
      <email>bmabe@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dianna Howard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Boughan, DO</last_name>
      <phone>216-844-7048</phone>
      <email>Kirsten.Boughan@UHhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Yeritza Hernandez-Collazo</last_name>
      <phone>216-844-8051</phone>
      <email>Yeritza.Hernandez-Collazo@UHhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kirsten Boughan, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Sobecks, MD</last_name>
      <phone>216-445-4626</phone>
      <email>sobeckr@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Nicolette Stiegerwald</last_name>
      <email>steigen@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Sobecks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman Saad, MD</last_name>
      <phone>614-293-3316</phone>
      <email>ayman.saad@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Von Derau</last_name>
      <email>Rebecca.VonDerau@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ayman Saad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Hayes-Lattin, MD</last_name>
      <phone>503-494-8534</phone>
      <email>hayeslat@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denise Lackey</last_name>
      <phone>503-494-1878</phone>
      <email>lackey@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brandon Hayes-Lattin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon McCurdy, MD</last_name>
      <phone>215-614-0698</phone>
      <email>shannon.mccurdy@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Raguza-Lopez</last_name>
      <phone>215-614-1852</phone>
      <email>maria.raguza.lopez@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shannon McCurdy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Aquino, MD</last_name>
      <phone>214-648-3896</phone>
      <email>victor.aquino@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beverly Williams</last_name>
      <email>Beverly.Williams2@childrens.com</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Aquino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Eames, MD</last_name>
      <email>Gretchen.Eames@cookchildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Sims</last_name>
      <phone>682-885-6920</phone>
      <email>jennifer.sims@cookchildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Gretchen Eames, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaQuisa Hill, MD</last_name>
      <phone>713-441-1450</phone>
      <email>LaQuisa.Hill@BCM.edu</email>
    </contact>
    <contact_backup>
      <last_name>Romelia May</last_name>
      <phone>713-441-6769</phone>
      <email>rmay@HoustonMethodist.org</email>
    </contact_backup>
    <investigator>
      <last_name>LaQuisa Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Ciurea, MD</last_name>
      <phone>713-745-0146</phone>
      <email>sciurea@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Vivian Al Jahdhami</last_name>
      <email>valjahdh@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Ciurea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ju-Hsien John Chao, DO</last_name>
      <phone>210-575-7870</phone>
      <email>juhsienjohn.chao@hcahealthcare.com</email>
    </contact>
    <contact_backup>
      <last_name>Lori Molbe</last_name>
      <email>Lorinda.Molbe@MHShealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ju-Hsien John Chao, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Lee, MD</last_name>
      <email>Catherine.lee@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Collind Boyington</last_name>
      <email>Collind.Boyington@hci.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamila Kindwall-Keller, DO</last_name>
      <phone>434-932-6406</phone>
      <email>tlk5de@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Almir Omerspahic</last_name>
      <email>ao6ug@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tamila Kindwall-Keller, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John McCarty, MD</last_name>
      <phone>804-828-4596</phone>
      <email>jmccarty@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathryn Candler</last_name>
      <phone>804-828-7432</phone>
      <email>kcandler@vcu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John McCarty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Lee, MD, MPH</last_name>
      <phone>206-667-6190</phone>
      <email>sjlee@fredhutch.org</email>
    </contact>
    <contact_backup>
      <last_name>Farah Sahoo</last_name>
      <phone>206-667-2898</phone>
      <email>fsahoo@fredhutch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Lee, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Juckett, MD</last_name>
      <phone>608-265-4363</phone>
      <email>mbj@medicine.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chris Waring</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mark Juckett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Jerkins, MD</last_name>
      <phone>414-805-4600</phone>
      <email>jjerkins@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kayla Peterson</last_name>
      <phone>414-805-0769</phone>
      <email>kpeterson@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Jerkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03904134/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

